A multicenter, randomized phase II trial for the treatment of locally advanced or metastatic NSCLC in stage IV UICC 7 with two different regimens of cisplatin / carboplatin and docetaxel in combination cetuximab [Multizentrische, randomisierte Phase II-Studie zur Therapie des lokal fortgeschrittenen oder metastasierten NSCLC im Stadium IV UICC 7 mit zwei unterschiedlichen Regimen von Cisplatin / Carboplatin und Docetaxel in Kombination mit Cetuximab].

Trial Profile

A multicenter, randomized phase II trial for the treatment of locally advanced or metastatic NSCLC in stage IV UICC 7 with two different regimens of cisplatin / carboplatin and docetaxel in combination cetuximab [Multizentrische, randomisierte Phase II-Studie zur Therapie des lokal fortgeschrittenen oder metastasierten NSCLC im Stadium IV UICC 7 mit zwei unterschiedlichen Regimen von Cisplatin / Carboplatin und Docetaxel in Kombination mit Cetuximab].

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2014

At a glance

  • Drugs Cetuximab (Primary) ; Carboplatin; Cisplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Merck Serono
  • Most Recent Events

    • 28 Jan 2014 Status changed from recruiting to discontinued, according to European Clinical Trials Database.
    • 27 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top